Trogenix Ltd., emerging from stealth mode, secured $95 million in Series A funding to propel its pipeline into clinical trials, focusing on a novel “Trojan horse” gene therapy approach targeting aggressive solid tumors. The flagship program targets glioblastoma multiforme, a highly malignant brain cancer. The financing supports clinical development and the company's strategic advancement toward potentially curative cancer therapies.